Navigation Links
Product Quotation Request - Microarray Spotting Solution for Silane Coated Slides from Sigma-Aldrich
... system uses the Adept CE 4100 high pressure ... UV/Visible detector for added flexibility and utra low ... alternative to a photodiode array detection and provides ... is required for method development and for monitoring ...
... is a new product number, created ... If showing no availability yet, please ... (E6152) or contact customer service for ... diam. 11.25 6.40 in. ...
... numbers of samples may be carried out using ... attention. System control and data processing is ... The elegant, powerful and very easy to ... 98 and 2000., The supplied detector is the ...
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
Biology Products:
(Date:8/18/2015)... 18, 2015  Navitas today announced that ... the Submission Content Management webinar scheduled on ... forum. Dedicated to the Implementation of Regulatory Submission ... for industry, vendors, health authorities, consultants and ... towards a standard method of implementing electronic ...
(Date:8/17/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Q4 2015. The new marketing campaign is being spearheaded ... Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ... in retail driven marketing and brand awareness and has ...
(Date:8/12/2015)... , August 12, 2015 ... of mobile payment innovation and advanced biometrics technology is ... the way consumers rely on using their credit cards, ... reinventing the future for payment services led by companies ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ), ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... demonstrated that morphine withdrawal complicates hepatitis C by suppressing ... Wang et al., Morphine withdrawal enhances hepatitis C virus ... The American Journal of Pathology and is accompanied by ... is common among intravenous drug users, with 70 to ...
... can result in two immune system disorders that ... severe infections, according to new findings reported in ... may lead to new diagnostic tests for these ... common variable immunodeficiency (CVID). Currently, doctors diagnose the ...
... a "time machine," assert Duke neuroscientists Catalin Buhusi and ... is essential to understanding all its functions. The brain's ... communicating, to orchestrating movement, to getting food, they said. ... Nature Reviews Neuroscience, Buhusi and Meck discuss the current ...
Cached Biology News:Hepatitis C complicated by morphine withdrawal 2Biologists Crack Genetic Code for Specialized Spider Silk 2Biologists Crack Genetic Code for Specialized Spider Silk 3What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brain's Internal Clock 2What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brain's Internal Clock 3What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brain's Internal Clock 4
(Date:8/27/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, ... Company Limited (Biohaven), announced today that dosing has ... a glutamate modulating agent. Biohaven filed an investigational ... clearance from the U.S. Food and Drug Administration ... 54% equity interest in Biohaven, a private company. ...
(Date:8/27/2015)... 27, 2015 GlassesOff (OTCBB: GLSO), a ... in the human vision system, announced today a partnership with ... Chris Paul to develop a new mobile app ... improve their real-life on-court performance. Vision is the ... is shooting a ball or blocking a pass. The critical ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... today that a second US laboratory is to open in Manhattan, Kansas in ... continued partnership and long-term growth of research and development through collaboration with researchers ...
(Date:8/26/2015)... Aug. 26, 2015  Platform therapeutic company Symic ... received a $1.5M Phase II SBIR grant from ... develop its therapeutic agent to reduce arteriovenous fistula ... end stage renal disease (ESRD) patients undergoing hemodialysis. ... of Diabetes and Digestive and Kidney Diseases (NIDDK), ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3